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Since 1996, the standard of care (SOC) therapy for HIV treatment has consisted of a back-
bone of two nucleoside analogue reverse transcriptase inhibitors (NRTI) paired with a third
agent. Use of two-drug combinations (2DC) has been considered for selected patients to
avoid toxicities associated with the use of NRTIs. This study aimed to compare the real-
world outcomes of integrase strand transfer inhibitor (INSTI)-containing triple therapy (TT)
to dolutegravir- (DTG) and/or boosted protease inhibitor (bPI)-based 2DC in a large Spanish
cohort of HIV patients.
Methods
A retrospective analysis was performed using data from the VACH cohort, a prospective
multicentre Spanish cohort of adult HIV patients. All treatment experienced patients initiating
a TT of an INSTI combined with two NRTIs or a 2DC-containing DTG and/or a bPI between
01/01/2012 and 01/06/2017 were included. The unit of analysis was patient-regimens. The
overall sample analysis was complemented with two sub-analyses. The first sub-analysis
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focused on patients treated with a backbone plus DTG compared to those treated with DTG
+ one other antiretroviral. The second sub-analysis focused on patients with HIV RNA<50
copies/mL at baseline, irrespective of the regimen used. The following endpoints were
assessed: time to discontinuation for any reason, time to switch due to virologic failure, and
time to switch due to toxicity (reasons for discontinuation according to clinician report in the
database). Time-to-event analyses were conducted using Kaplan–Meier survival curves
and Cox regression models.
Results
Overall 7,481 patients were included in the analysis, contributing to 9,243 patient-regimens.
Patient characteristics at baseline differed among groups, with the 2DC group being signifi-
cantly older and having a higher proportion of women, a longer time on ART and a higher
number of previous virologic failures. Median (95% Confidence Interval [C.I.]) time to switch
was 2.5 years (2.3, 2.7) in 2DC group versus 2.9 years (2.7, 3.0) in TT. Adjusted hazard
ratios (95% C.I.) for discontinuation due to any reason, virologic failure and toxicity in the
2DC vs TT group were 1.29 (1.15; 1.44), 2.06 (1.54; 2.77) and 1.18 (0.94; 1.48), respec-
tively. Results were consistent in the two sub-analyses.
Conclusion
In this analysis, time to discontinuation and probability of remaining free of virologic failure
were significantly higher in patients on INSTI-based TT compared to DTG- and/or bPI-con-
taining 2DC, with no differences in toxicity.
Introduction
In 2016, there were 160,453 people newly diagnosed with HIV in 51 of the 53 countries in the
World Health Organization (WHO) European Region, which corresponds to a rate of 18.2
newly diagnosed infections per 100,000 population [1]. Moreover, it is estimated that approxi-
mately 15% of those living with HIV in the European Union (EU) and European Economic
Area (EEA) are not aware of their status [1].
Although the clinical, immunological, and virologic course of untreated HIV infection is
variable, few untreated persons followed for more than 8–10 years remain without any evi-
dence of disease progression [2]. The majority of the patients who do not receive antiretroviral
therapy (ART) die within 2 years of the onset of acquired immunodeficiency syndrome
(AIDS) [3].
Improvements in ART have transformed HIV from a terminal to a chronic disease. Patients
who started ART in 2008–10 and are able to reach CD4+ T cell counts (CD4) of at least 350
cells/μL within one year after ART initiation have an estimated life expectancy approaching
that of the general population [4].
ART itself has evolved over time from monotherapy to triple therapy (TT). The recom-
mended combination regimen for treatment initiation consists of two nucleoside analogue
reverse transcriptase inhibitors (NRTI) (“backbone”) paired with a third agent [5]. Since 1996,
TT has been the standard of care therapy in HIV treatment.
Despite improvements in TT regimens, long-term toxicity of tenofovir disoproxil fumarate
(TDF) and abacavir (ABC), led clinicians and researchers to look for solutions to help people
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living with HIV achieve the best possible long-term health. Exploratory strategies such as two-
drug combinations (2DC) have been considered where neither TDF nor ABC are optimal
options.
2DC strategies have been used in the past. With few exceptions, 2DC strategies have been
associated with higher rates of virologic failure than TT in the clinical trial setting [5]. How-
ever, the SWORD 1&2 [6] randomized clinical trials showed that switching to dolutegravir
(DTG) + rilpivirine (RPV) was non-inferior to remaining on TT in patients stably sup-
pressed (viral load <50 copies per mL) for at least 6 months with no hepatitis B virus (HBV)
coinfection, no history of virologic failure on a prior regimen, and no history of any resis-
tance associated major protease inhibitors (PI), integrase strand transfer inhibitor (INSTI),
NRTI, or non-nucleoside analogue reverse transcriptase inhibitors (NNRTI) mutation. In
line with the SWORD 1&2 results, the TANGO randomized trial [7] demonstrated non-infe-
riority of switching to DTG/lamivudine (3TC) when compared to maintaining a tenofovir
alafenamide (TAF)-containing regimen of at least three drugs, among patients suppressed
for at least 6 months, without prior virologic failure, no historical NRTI or INSTI major
resistance mutation, and no evidence of HBV infection. Lastly, the GEMINI 1&2 [8] ran-
domized clinical trials showed that DTG+3TC was non-inferior to emtricitabine (F)/TDF
+DTG in carefully selected treatment naïve patients with HIV-1 RNA�500,000 copies/mL,
CD4 >200 cells/mL, no HBV coinfection, and no known resistance associated major PI,
INSTI, NRTI, or NNRTI mutations.
One of the main concerns with 2DC is the potential for a lower resistance barrier, which
may be more problematic with poorer adherence. Exclusion criteria for HIV treatment drug
trials can be stringent and selection bias exists, making it difficult to extrapolate results into
’real-world’ settings [9]. Average adherence in the clinical trial setting is often at least 95% [10,
11] while in the real-world it is often below 80% [12] with a significant proportion of patients
experiencing treatment gaps [13]. While older TT regimens required 95% adherence for opti-
mal effectiveness [14–16], there is currently evidence to support that more contemporary TT
regimens are more “forgiving” of suboptimal adherence; indeed, >80% adherence may be
enough to maintain suppression [15–17].
Given the potential discrepancy between randomized clinical trials and effectiveness in
real-world settings, this study aimed to evaluate the outcomes of INSTI-containing TT to
DTG- and/or boosted PI (bPI)-containing 2DC in a large, Spanish, cohort of HIV patients.
Materials and methods
Data collection
The VACH cohort is a prospectively recruited Spanish cohort of 14,833 HIV-infected adult
patients from 23 investigational centres across Spain. Enrollment started in 1997. Data are pro-
spectively collected in an electronic case record form according to standardized criteria and
are electronically stored in the Aplicación de Control Hospitalario (AC&H™). This application
was specifically developed for the management of the cohort data: demographic data, HIV risk
factors, Centers for Disease Control and Prevention stage according to 1993 definitions, HIV-
1 treatment initiation date, the specific antiretroviral regimens used, the date of change of
every drug and the reasons for change, CD4 cell count, plasma HIV RNA levels, blood cell
counts and blood chemistry tests. Data are periodically recorded at each patient visit at inter-
vals of approximately 3–4 months. All collected information is transformed into a standard-
ized format and merged into a central dataset. The data passes an internal duplicate control
at the central data centre that identifies patients by a unique code. Internal validation
controls and quality controls of the data are used. Informed consent not required given the
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de-identified nature of the data. The study was reviewed and approved by Ethics Review Board
of Cantabria IDIVAL.
Patient selection
All patients in the VACH cohort switching between January 1st, 2012 and June 1st, 2017 were
considered and checked for inclusion and exclusion criteria.
Only patients switching to the following regimens were considered:
• INSTI-containing TT: elvitegravir/cobicistat (E/C), raltegravir (RAL) or DTG combined
with one of the following 2 NRTI backbones: emtricitabine (F)/TDF or 3TC/abacavir (ABC)
or F/TAF.
• DTG or bPI–based 2DC: DTG or boosted (b) darunavir (DRV) or b-atazanavir (ATV) or b-
lopinavir (LPV) combined with 3TC; DTG or bDRV combined with RPV; bDRV or bLPV
combined with RAL; DTG plus bDRV
The unit of analysis was the patient-regimen, defined as a patient on a specific regimen.
This meant that a given patient could contribute multiple times to the data if during the rele-
vant period of analysis, they initiated a regimen of interest more than once. Patient-regimens
were followed from date of regimen switch to discontinuation, loss-to-follow up, death or end
of the observation period (June 30th, 2017), whichever happened first.
The following exclusion criteria were applied: (1) If an individual had participated in an
interventional clinical trial while on a specific regimen, that patient-regimen information was
excluded but the remaining patient-regimens for that individual during the study period
would be included if eligible; (2) patient-regimens were excluded if reason of discontinuation
of the previous regimen was: loss to follow-up, programmed interruption, intermittent treat-
ment or intention of restoring wild type virus. Patient-regimens with data inconsistencies that
could not be corrected were also excluded.
Statistical analysis
Patient-regimens were stratified according to the type of ART regimen: TT versus 2DC. Base-
line characteristics were compared using the Student’s t-test to compare two means and the χ2
test for categorical variables if all cells had expected counts more than 5; otherwise Fisher’s
exact test was used.
The univariate and multivariate analyses performed targeted the following endpoints of
interest: time to discontinuation for any reason, time to discontinuation due to virologic fail-
ure, time to discontinuation due to toxicity (classified in the database as due to adverse event,
intolerance, avoiding long-term toxicity or drug interactions). Reasons for discontinuation
were based on the clinicians’ report in the database.
Time-to-event analyses were conducted using Kaplan–Meier survival curves, comparing
both groups via the log-rank test and the Cox proportional regression analysis. As potential
confounders, the following variables were initially introduced in the Cox regression analysis:
age, gender, AIDS diagnosis ever (Y/N: Yes/No), hepatitis C virus (HCV) (Y/N) co-infection,
HBV (Y/N) co-infection, illicit drug use ever (Y/N), HIV RNA (copies/mL), CD4 counts
(cells/mm3), duration on ART, number of previous ART regimens, number of previous viro-
logic failures. All covariates were evaluated at patient-regimen initiation unless otherwise
stated. Confounders with more than 20% of missing values were not included in the Cox
model. A stepwise selection was used to select the covariates to be included in the final model
using a p-value of 0.25 to enter the model and a p-value of 0.10 to remain in the model.
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The analysis was performed on the overall sample as well as two pre-defined sub-analyses:
(1) DTG-containing TT versus DTG-containing 2DC, and (2) all TT versus 2DC, among
patients in the overall sample suppressed (defined as HIV RNA<50 copies/mL) at baseline.
All analyses were performed using SAS (Version 9.4, The SAS institute, Cary, NC).
Results
Overall sample
Antiretroviral regimen distribution and baseline characteristics. Overall, 7,481 patients
were included in the analysis, contributing 9,243 patient-regimens. Out of the 7,481 distinct
patients, 5,992 contributed to the TT group with 7,371 patient-regimens and 1,489 contributed
to the 2DC group with 1,872 patient-regimens. 48 patient-regimens were excluded because of
the reason for discontinuation of the previous regimen (92% discontinued due to intermittent
treatment) and 19 because of unresolvable data inconsistencies. As shown in Table 1, DTG/
+3TC/ABC (that is, in a single tablet or 2 pills) and E/C/F/TAF accounted for almost two
thirds of the patient-regimens in TT; 60% of the 2DC regimens consisted of bDRV combined
with either 3TC or RAL, and DTG+RPV (two pills given that at the time of the study no 2DC
single tablet regimen was available).
Statistically significant differences were observed between the two groups as detailed in
Table 2. At baseline, the 2DC group was older (mean age 50.0 vs 47.4, p<0.0001) and included
a higher proportion of women (27.8% vs 23.1%, p<0.0001). The 2DC group had a higher pro-
portion of patients co-infected with HCV (47.2% vs. 39.4%, p<0.0001) and more patients with
history of illicit drug use (40.3% vs. 32.9%, p<0.0001) compared to the TT group. Patients
on 2DC had been on ART for 3 years longer on average than the TT group (14.6 vs. 11.6,
p<0.0001), were more likely to have had a previous AIDS diagnosis (32.3% vs. 24.9%,
p<0.0001) and had a higher number of previous virologic failures (2.3 vs. 1.0, p<0.0001).
End of follow-up status, overall sample. Overall, the TT group contributed 8,307
patient-years of follow-up while the 2DC group contributed 2,154 patient-years. By the end of
follow-up period, a higher proportion of patients had switched treatment in the 2DC group
(31.4% vs. 24.2%) with a primary contributor being switch due to virologic failure. A
Table 1. Antiretroviral therapy distribution, overall sample, by therapy group.
Triple Therapy (TT) Two-Drug Combinations (2DC)
ART Regimen N (%) ART Regimen N (%)
DTG/+3TC/ABC� 2686 (36.4%) bDRV + 3TC 548 (29.3%)
E/C/F/TAF 1883 (25.6%) DTG + RPV 293 (15.7%)
E/C/F/TDF 1083 (14.7%) bDRV + RAL 292 (15.6%)
F/TDF+RAL 739 (10.0%) DTG + bDRV 249 (13.3%)
3TC/ABC+RAL 576 (7.8%) bDRV + RPV 207 (11.1%)
F/TDF+DTG 404 (5.5%) DTG + 3TC 146 (7.8%)
bLPV + 3TC 95 (5.1%)
bLPV + RAL 42 (2.2%)
ART: antiretroviral therapy; 3TC: lamivudine; ABC: abacavir; DTG: dolutegravir; F: emtricitabine; TAF: tenofovir
alafenamide; TDF: tenofovir disoproxil fumarate; E/C: elvitegravir/cobicistat; b: booster; RAL: raltegravir; bDRV:
boosted darunavir; RPV: rilpivirine; bLPV: boosted lopinavir.
�While most patient-regimens were on DTG/3TC/ABC (one tablet) some were on two tablets (3TC/ABC) + DTG.
For the purpose of the present analysis, no distinction was made between the two and DTG/+3TC/ABC is used as
notation for both cases.
https://doi.org/10.1371/journal.pone.0249515.t001
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significantly higher number of 2DC patient-regimens discontinued due to virologic failure
compared to TT (14.0% vs 6.7%, p<0.0001) (Table 3). There was no significant difference in
discontinuations due to adverse events. A higher proportion of patients discontinued in the
TT group to avoid long-term toxicities (4.5% vs 1.2%, p = 0.0002). It is worth noting that the
proportion lost to follow-up was identical (8.6%) in both groups in this real-world setting
which is one important marker of similarity between the two cohorts.
Survival analysis, overall sample. Fig 1 presents the Kaplan-Meier unadjusted analysis
for time to discontinuation, stratified by reason for discontinuation. Longer time to discontin-
uation for any reason was observed in the TT group, where the probability of persistence at 5
years was 30.3% compared to 7.7% in the 2DC. Median time to discontinuation for any reason
was 0.4 years longer in the TT group (2.9 vs. 2.5 years, p<0.0001) (Fig 1a). When exploring
reasons for and time to discontinuation, there was a statistically significant difference in dis-
continuations due to virologic failure in favor of the TT group (p<0.0001) (Fig 1b). There was
no statistically significant difference in discontinuation due to toxicity (p = 0.66), as shown in
Fig 1c.
Table 2. Sociodemographic and clinical characteristics at baseline, overall sample.
Characteristics at Baseline Triple Therapy (N = 5,992 patients, 7,371
patient-regimens)
Two-Drug Combinations (N = 1,489 patients, 1,872
patient-regimens)
P-value�
Age, Mean (SD) 47.4 (10.1) 50.0 (9.2) < .0001
Male 76.9% 72.2% < .0001
Country of Origin, % 0.008
Spain 72.8% 75.8%
Other 27.2% 24.2%
HIV Transmission Risk Group < .0001
Heterosexual 29.1% 33.2%
Homosexual or Bisexual 35.0% 23.9%
People Who Inject Drugs 33.7% 40.9%




Age at Diagnosis, Mean (SD) 33.3 (10.2) 32.6 (10.4) 0.017
Prior AIDS Diagnostic, Yes 24.9% 32.3% < .0001
Nadir CD4+ T cell count < .0001
<50 cells/μL 17.1% 24.1%
51–200 cells/μL 32.7% 36.8%
201–350 cells/μL 27.2% 25.0%
�350 cells/μL 23.0% 14.1%
CD4+ T cell count <350 cells/μL 23.4% 22.8% 0.618
HIV RNA <50 copies/mL 76.9% 74.6% 0.034
Illicit drug use, Yes 32.9% 40.3% < .0001
Hepatitis C virus coinfection, Yes 39.4% 47.2% < .0001
Hepatitis B virus coinfection, Yes 4.7% 1.6% < .0001
Number of years on ART, Mean (SD) 11.6 (7.5) 14.6 (7.2) < .0001
Number of previous ART regimens,
Mean (SD)
4.4 (3.6) 7.0 (5.3) < .0001
Number of virologic failures, Mean (SD) 1.0 (1.8) 2.3 (3.7) < .0001
SD: standard deviation; HIV: Human immunodeficiency virus; AIDS: acquired immunodeficiency syndrome; RNA: ribonucleic acid; ART: antiretroviral therapy; RNA;
ribonucleic acid.
https://doi.org/10.1371/journal.pone.0249515.t002
PLOS ONE Effectiveness of triple therapy versus two-drug combinations
PLOS ONE | https://doi.org/10.1371/journal.pone.0249515 April 8, 2021 6 / 14
Table 3. Status at end of observation period, overall sample, by treatment group.
End of the Observation Period Status, N (%) Triple Therapy (TT) Two-Drug Combinations (2DC) P-value�
Remained on treatment 4919 (66.7%) 1110 (59.3%)
Change of treatment 1779 (24.2%) 587 (31.4%)
Due to Virologic failure 119 (6.7%) 82 (14.0%) < .0001
Due to Adverse event 372 (20.9%) 104 (17.7%) 0.094
Due to Intolerance 11 (0.6%) 4 (0.7%) 0.773
To Avoid Long-Term Toxicities 80 (4.5%) 7 (1.2%) 0.0002
Due to Simplification 320 (18.0%) 98 (16.7%) 0.477
Due to Drug Interactions 79 (4.4%) 21 (3.6%) 0.368
Due to Lost to Follow-up 18 (1.0%) 3 (0.5%) 0.320
Due to Others 764 (43.0%) 264 (45.0%) 0.389
Missing value 16 4
Lost to follow-up 637 (8.6%) 161 (8.6%)
Death 36 (0.5%) 14 (0.8%)
https://doi.org/10.1371/journal.pone.0249515.t003
Fig 1. Kaplan-Meier curve for two-drug combinations versus triple therapy: a) time to discontinuation), b) switch due to virologic failure, c)
switch due to toxicity. TT: triple therapy; 2DC: two-drug combination.
https://doi.org/10.1371/journal.pone.0249515.g001
PLOS ONE Effectiveness of triple therapy versus two-drug combinations
PLOS ONE | https://doi.org/10.1371/journal.pone.0249515 April 8, 2021 7 / 14
As previously described, some baseline characteristics differed among groups. It was thus
important to account for potential confounders in multivariate regression. Table 4 shows the
adjusted hazard ratios (aHR) obtained from the final model of the Cox Proportional hazard
regression. Consistent with results of the Kaplan-Meier analysis, the risk of discontinuation
for any reason was 29% (95% C.I.: [15%, 44%], p<0.0001) higher in the 2DC group compared
to the TT group. The risk of discontinuation for virologic failure was also significantly higher
in the 2DC group (aHR: 2.06, 95% C.I. [1.54, 2.77], p<0.0001). Differences in switches due to
toxicity were not statistically significant (aHR: 1.18 [0.94, 1.48], p = 0.16).
Sub-samples: (1) dolutegravir-containing triple therapy versus
dolutegravir-containing two-drug combinations and (2) HIV RNA<50
copies/mL at switch
Antiretroviral therapy and patients´ baseline characteristics. In the DTG-containing
sub-analysis, all patient-regimens including DTG were included. Patient-regimens were then
divided in two groups: DTG-containing TT (N = 3,090) and DTG-containing 2DC (N = 688).
The distribution by antiretroviral combination is described in Table 5. Almost 90% were on
Table 4. Final Cox model for two-drug combinations versus triple therapy time to discontinuation, switch due to virologic failure and switch due to toxicity, overall
sample.
Hazard Ratio [95% Confidence Interval], P-value
Characteristics at initiation of the patient-regimen Time to Discontinuation Switch Due to Virologic Failure Switch Due to Toxicity
Therapy group (2DC vs TT) 1.29 [1.15, 1.44], p<0.0001 2.06 [1.54, 2.77], p<0.0001 1.18 [0.94, 1.48], p = 0.16
Age, per year older 1.00 [1.00, 1.01], p = 0.09 1.01 [1.00, 1.02], p = 0.003
Hepatitis B virus coinfection, (Y/N) 1.31 [1.06, 1.62], p = 0.013 1.39 [0.93, 2.06], p = 0.11
Illicit drug use, (Y/N) 1.33 [1.20, 1.47], p<0.0001 1.40 [1.05, 1.85], p = 0.021
Male (Y/N) 0.88 [0.79, 0.97], p = 0.013
HIV RNA (�50 vs. < 50) 1.44 [1.30, 1.59], p<0.0001 4.68 [3.51, 6.23], p<0.0001
Years on antiretroviral therapy 0.96 [0.95, 0.97], p<0.0001 0.89 [0.88, 0.91], p<0.0001
Number of previous regimens 1.06 [1.04, 1.07], p<0.0001 1.07 [1.06, 1.09], p<0.0001 1.12 [1.08, 1.17], p<0.0001
Number of previous virologic failures 0.92 [0.86, 0.97], p = 0.0039
Y/N: Yes/No; 2DC: two-drug combination; TT: standard of care triple therapy; HIV: Human Immunodeficiency Virus; RNA: ribonucleic acid.
Note: Grey boxes reflect variables that were dropped in stepwise regression considering a 0.2 cut-off.
https://doi.org/10.1371/journal.pone.0249515.t004
Table 5. Antiretroviral therapy distribution within dolutegravir containing therapy sub-sample, by treatment
group.
Antiretroviral Therapy Percentage
Triple Therapy (n = 3,090)
DTG /+ 3TC /ABC 86.9%
F/TDF + DTG 13.1%
Two-Drug Combinations (n = 688)
DTG + RPV 42.6%
DTG + bDRV 36.2%
DTG + 3TC 21.2%
DTG: dolutegravir; 3TC: lamivudine; ABC: abacavir; F: emtricitabine; TDF: tenofovir disoproxil fumarate; RPV:
rilpivirine; bDRV: boosted darunavir.
https://doi.org/10.1371/journal.pone.0249515.t005
PLOS ONE Effectiveness of triple therapy versus two-drug combinations
PLOS ONE | https://doi.org/10.1371/journal.pone.0249515 April 8, 2021 8 / 14
DTG/+3TC/ABC in the DTG-containing TT group, and DTG + RPV was the most frequent
combination (42.6%) in the DTG-containing 2DC group.
The subset of suppressive patient-regimens was defined as those with HIV RNA <50 cop-
ies/mL at switch. Among suppressed at switch patients, the distribution of ART combinations
was similar to that of the overall sample (Tables 5 and 6). A total of 6,982 patient-regimens
were included in this sub-analysis, with 20% of those contributing to the 2DC group.
A detailed description of baseline sociodemographic and clinical characteristics for each of
the sub-analyses is provided in the S1 Table. In essence, the pattern in each of the subsamples
was similar to that of the overall sample.
In the DTG-containing subsample, patients in the 2DC group were older than those on TT
(mean age: 50.6 vs. 48.9 years, p<0.0001), and there was a higher proportion of women in the
2DC group compared to the TT group (32.4% vs. 23.4%, p<0.0001). A higher proportion of
patients with prior AIDS diagnoses was also observed in the 2DC group (32.1% vs. 25.8%,
p = 0.0008). The 2DC group was also more experienced than the TT group, with an average
number of prior regimens of 7.8 vs. 4.6 (p<0.0001). In contrast to the overall sample and the
suppressed at switch sub-group, differences in HCV coinfection and illicit drug use were not
statistically significant (HCV: 42.7% vs. 39.8%, p = 0.187; illicit drug use: 35.0% vs. 32.7%,
p = 0.244).
In the suppressed at baseline subsample, patients in the 2DC group were older than those
on TT (mean age: 50.7 years-old vs. 48.0 years-old, p<0.0001). There was a higher proportion
of women in the 2DC group compared to TT group (27.2% vs. 22.9%, p = 0.001) and a higher
proportion of patients with prior AIDS diagnoses (29.9% vs. 23.6%, p<0.0001). The 2DC
group was also more treatment-experienced than the TT group, with an average number of
prior regimens of 7.0 vs. 4.4 (p<0.0001). The proportion of patients with HCV diagnosis was
higher in the 2DC group than in the TT group (39.0% vs. 47.5%, p<0.0001), as was the propor-
tion of patients with history of illicit drug use (32.6% vs. 40.8%, p<0.0001)
Table 6. Antiretroviral therapy distribution within suppressed at baseline sub-sample, by treatment group.
Antiretroviral Therapy Percentage
Triple Therapy (n = 5,596)






Two-Drug Combinations (n = 1,386)
bDRV + 3TC 31.6%
DTG + RPV 16.9%
bDRV + RAL 13.9%
bDRV + RPV 10.9%
DTG + 3TC 9.9%
DTG + bDRV 9.4%
bLPV + 3TC 5.9%
bLPV + RAL 1.5%
DTG: dolutegravir; 3TC: lamivudine; ABC: abacavir; E/C: elvitegravir/cobicistat, F: emtricitabine; TAF: tenofovir
alafenamide; TDF: tenofovir disoproxil fumarate; RAL: raltegravir; bDRV: boosted darunavir; RPV: rilpivirine;
bLPV: boosted lopinavir.
https://doi.org/10.1371/journal.pone.0249515.t006
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End of follow-up status. At the end of the observation period, consistent with the overall
sample analysis, more patients on TT persisted on the regimen compared to patients on 2DC.
In the DTG-containing sub-analysis 80.4% of the TT group versus 71.8% of the 2DC group
remained on the regimen. In the suppressed at baseline sub-analysis, 69.9% of the TT group
versus 63.3% of the 2DC group remained on the regimen.
A lower proportion of virologic failures occurred in the TT group compared to the 2DC
group (DTG-containing sub-analysis: 8.2% vs. 18.7%; HIV RNA<50 copies/mL at baseline
sub-analysis: 3.8% vs. 8.1%).
In the DTG-containing sub-analysis, the proportion of patients discontinuing treatment
due to adverse events was higher in the TT group (21.8% vs 11.7%, p = 0.004), but there
was no difference between groups in the suppressed patient sub-analysis (21.9% vs. 20.4%,
p = 0.542).
Switches to avoid long-term toxicity did not differ in the DTG-containing sub-analysis
(p = 0.122) but occurred more frequently in the TT group when considering patients with
HIV RNA<50 copies/mL at baseline (5.4% vs. 1.2%, p<0.001), (S2 Table).
Time to event. Results in both sub-analyses were consistent with those of the overall sam-
ple. Fig 2 summarizes aHR for 2DC vs TT by reason for discontinuation (any reason, virologic
failure and toxicity) and each of the samples considered (overall, DTG-containing and sup-
pressed at switch).
In all analyses, time to discontinuation was significantly longer in the TT group. In the
DTG-containing sub-analysis, the risk of discontinuation due to any reason was 49% higher in
the 2DC group (aHR: 1.49, 95% C.I. [1.22; 1.83]). Risk of virologic failure was also significantly
higher in the 2DC group: almost 3-fold higher in the DTG-containing sub-analysis (aHR: 2.78,
95% C.I. [1.71; 4.51]) and almost 2-fold higher (aHR: 1.86, 95% C.I. [1.15; 3.02]) in the HIV
RNA<50 copies/mL at baseline sub-analysis. Discontinuation due to adverse events was simi-
lar between groups.
Fig 2. Adjusted hazard ratio for two-drug combinations versus triple therapy forest plot, by sample and endpoint. DTG: dolutegravir; 2DC: 2 drug
combinations; TT: triple therapy.
https://doi.org/10.1371/journal.pone.0249515.g002
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Discussion
In the present study, persistence and probability of remaining free of virologic failure were sig-
nificantly higher in patients on INSTI-based TT compared to DTG and/or PI/r containing
2DC, with no difference in toxicity. In fact, the present analysis suggests that the risk of viro-
logic failure is at least two times higher with 2DC vs TT when considering both the overall
sample and the DTG-containing sub-sample. Perhaps even more relevant is the finding that
among patients suppressed at baseline, the risk of virologic failure after controlling for con-
founders, remained almost twice as high in the 2DC vs TT group. This negative impact in
terms of virologic failure associated with 2DC was not compensated by a reduction in discon-
tinuations due to adverse events, thus limiting the evidence supporting a switch to 2DC for
toxicity reasons.
TT has been firmly established as an efficacious and effective treatment option over the last
20 years, both in clinical trials [14] and the real-world setting [15, 16]. However, real-world
evidence supporting the effectiveness of bPI+3TC, DTG+3TC or DTG+RPV 2DC is limited
[17, 18].
The present analysis contributes to the limited body of evidence of real-world effectiveness
of contemporary TT and DTG and/or bPI 2DC regimens. To our knowledge this is the first
analysis to compare DTG-containing TT to DTG-containing 2DC in the real-world and the
results reinforce those of the overall analysis, indicating a significantly higher probability of
virologic failure with DTG-containing 2DC with no statistically significant difference in terms
of discontinuations due to adverse events. This may seem at odds with the results of the
SWORD 1&2 randomised clinical trials, which demonstrated non-inferior efficacy of the com-
bination of DTG plus RPV to that of a previous and on-going standard TT [6]. A likely expla-
nation for this discrepancy relies on the differences in the baseline characteristics between the
populations studied in the SWORD 1&2 and in our analysis: participants in the trials were on
their first or second line of treatment and were included only if they had not experienced a
virological failure and had an excellent virological control in the preceding months. In con-
trast, the patients in our study were unselected for their past antiretroviral treatment history or
virological failure, and were not excluded if the viral load was detectable at the baseline visit.
Taken together, both sets of analyses lead to a seemingly coherent hypothesis that, in carefully
selected patients (with the characteristics defined as inclusion criteria in the SWORD trials)
DTG plus RPV 2DC is as effective as INSTI-based TT, whereas in cases with a less favorable
ART background TT provides a significant benefit. It is of concern that the relatively high pro-
portion of patients were switched to a 2DC regimen in suboptimal conditions relative to their
ART history. This may be due to the fact that research in so called “less drug regimens” (mono-
therapy and later 2DC) became very popular in Spain in recent years. Many clinicians became
familiar and confident with the use of these oversimplified regimens, probably straining on
occasions their indications.
Our analysis has strengths and limitations. Among strengths, the sample size was large,
incorporating current TT regimens, including F/TAF-based single-tablet regimens, which,
because of their improved safety profile, minimize the toxicity associated with some older TT.
The study inclusion criteria specifically excluded 2DC regimens mentioned as not recom-
mended by the European AIDS Society guideline V9.1 (pp. 15 “Strategies not recommended”)
[5] and included the largest number to date of patients on 2DC classified as alternatives. Also,
patient-regimens that occurred in the framework of a clinical trial were excluded to better
reflect the real-world setting. Finally, the observed findings concerning the relationship
between current 2DCs and discontinuation occurred in the context of multivariate analysis
where, in as much as data were available, differences between groups were controlled for.
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The most important limitation of the study is the likelihood of confounding by indication
since clinicians select the most adequate treatment for a given patient with far more informa-
tion than that collected by means of variables in the VACH cohort. It is also unknown if the
outcomes of persistence, time to virologic failure, or discontinuations due to adverse events
would have been similar to those obtained by patients treated with TT if patients treated with
2DC had been given TT; the aim of the analysis was simply to describe what occurs in clinical
practice without an attempt to predict what would have happened in a distinct clinical setting.
Patient characteristics were different in the 2DC and TT groups, pointing to a potential worse
adherence to treatment of 2DC patients that could impact results despite the efforts to control
for confounders. In addition, several covariates of interest were incompletely recorded in the
database, precluding their inclusion in the regression analysis. There is an unquestionable het-
erogeneity in the list of 2DC included in the study. Among a larger list having been used in the
Cohort, which was available in the database, we selected those combinations supported by at
least one randomised clinical trial, but not necessarily for treatment switches in pre-treated
patients (the only exception being the combination of DTG+bDRV). Also, it must be taken
into account that at the time of the analyses all 2DC considered were only available as multi-
tablet regimens. Last but not least, all available information was used to minimize confound-
ing, namely by including the number of previous virologic failures since ART initiation, num-
ber of previous switches for any reason as well as clinical and demographic characteristics.
Despite that, the impact of the NRTI backbone, qualitatively specific previous regimens, non-
adherence, or other unobservable confounders (not captured in the proxies used) on the
results of this study cannot be ruled out.
To provide quality care, minimize adverse events, and improve the lives of patients living
with HIV, it is critical to investigate real-world effectiveness of ART regimens. As new ART
regimens are developed, great care should be taken to establish real-world efficacy and viral
suppression prior to implementation.
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